Literature DB >> 29450732

Combined prostatic urethral lift and remodeling of the prostate and bladder neck: a modified transurethral approach in the treatment of symptomatic lower urinary tract obstruction.

Martin Schoenthaler1, Karl-Dietrich Sievert2, Dominik Stefan Schoeb1, Arkadiusz Miernik1, Thomas Kunit3, Simon Hein1, Thomas R W Herrmann4, Konrad Wilhelm5.   

Abstract

PURPOSE: The aim of the study was to evaluate the feasibility and safety of combining prostatic urethral lift (PUL) and a limited resection of the prostatic middle lobe or bladder neck incision in the treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH).
METHODS: Twenty-eight patients were treated at two tertiary centers and followed prospectively. Patient evaluations included patient characteristics, relief of LUTS symptoms, erectile and ejaculatory function, continence, operative time and adverse events. Patients were followed for a mean of 10.9 months.
RESULTS: Patient characteristics were as follows: age 66 years (46-85), prostate volume 39.6 cc (22-66), preoperative IPSS/AUASI 20 (6-35)/QoL 3.9 (1-6)/peak flow 10.5 mL/s (4.0-19)/post-void residual volume (PVR) 123 mL (0-500). Mean operating time was 31 min (9-55). Postoperative complications were minor except for the surgical retreatment of one patient for blood clot retention (Clavien 3b). One patient required catheterization due to urinary retention. Reduction of symptoms (IPSS - 59.6%), increase in QoL (+ 49.0%), increase in flow (+ 111.5%), and reduction of PVR (- 66.8%) were significant. Antegrade ejaculation was always maintained.
CONCLUSION: Our data suggest that a combination of PUL and transurethral surgical techniques is feasible, safe, and effective. This approach may be offered to patients with moderate size prostates including those with unfavorable anatomic conditions for PUL. This procedure is still 'minimally invasive' and preserves sexual function. In addition, it may add to a higher functional efficacy compared to PUL alone. STUDY REGISTER NUMBER: DRKS00008970.

Entities:  

Keywords:  Ejaculation; Lower urinary tract symptoms; Prostatic urethral lift; Transurethral resection of prostate

Mesh:

Year:  2018        PMID: 29450732     DOI: 10.1007/s00345-018-2232-8

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  22 in total

1.  [Anatomic principles of urinary incontinence].

Authors:  W Dorschner; J U Stolzenburg; J Neuhaus
Journal:  Urologe A       Date:  2001-05       Impact factor: 0.639

2.  Multicentre prospective crossover study of the 'prostatic urethral lift' for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.

Authors:  Anthony L Cantwell; William K Bogache; Steven F Richardson; Ronald F Tutrone; Jack Barkin; James E Fagelson; Peter T Chin; Henry H Woo
Journal:  BJU Int       Date:  2014-04       Impact factor: 5.588

3.  Update on AUA guideline on the management of benign prostatic hyperplasia.

Authors:  Kevin T McVary; Claus G Roehrborn; Andrew L Avins; Michael J Barry; Reginald C Bruskewitz; Robert F Donnell; Harris E Foster; Chris M Gonzalez; Steven A Kaplan; David F Penson; James C Ulchaker; John T Wei
Journal:  J Urol       Date:  2011-03-21       Impact factor: 7.450

4.  The smooth sphincter of the vesical neck, a genital organ.

Authors:  P Gallizia
Journal:  Urol Int       Date:  1972       Impact factor: 2.089

5.  180-W XPS GreenLight laser vaporisation versus transurethral resection of the prostate for the treatment of benign prostatic obstruction: 6-month safety and efficacy results of a European Multicentre Randomised Trial--the GOLIATH study.

Authors:  Alexander Bachmann; Andrea Tubaro; Neil Barber; Frank d'Ancona; Gordon Muir; Ulrich Witzsch; Marc-Oliver Grimm; Joan Benejam; Jens-Uwe Stolzenburg; Antony Riddick; Sascha Pahernik; Herman Roelink; Filip Ameye; Christian Saussine; Franck Bruyère; Wolfgang Loidl; Tim Larner; Nirjan-Kumar Gogoi; Richard Hindley; Rolf Muschter; Andrew Thorpe; Nitin Shrotri; Stuart Graham; Moritz Hamann; Kurt Miller; Martin Schostak; Carlos Capitán; Helmut Knispel; J Andrew Thomas
Journal:  Eur Urol       Date:  2013-11-11       Impact factor: 20.096

6.  The mechanisms of ejaculation.

Authors:  H Marberger
Journal:  Basic Life Sci       Date:  1974

7.  Ejaculation-preserving transurethral resection of prostate and bladder neck: short- and long-term results of a new innovative resection technique.

Authors:  Saladin Helmut Alloussi; Christoph Lang; Robert Eichel; Schahnaz Alloussi
Journal:  J Endourol       Date:  2013-10-10       Impact factor: 2.942

8.  Safety and feasibility of the prostatic urethral lift: a novel, minimally invasive treatment for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH).

Authors:  Henry H Woo; Peter T Chin; Thomas A McNicholas; Harcharan S Gill; Mark K Plante; Reginald C Bruskewitz; Claus G Roehrborn
Journal:  BJU Int       Date:  2011-05-06       Impact factor: 5.588

Review 9.  EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction.

Authors:  Christian Gratzke; Alexander Bachmann; Aurelien Descazeaud; Marcus J Drake; Stephan Madersbacher; Charalampos Mamoulakis; Matthias Oelke; Kari A O Tikkinen; Stavros Gravas
Journal:  Eur Urol       Date:  2015-01-19       Impact factor: 20.096

10.  Minimally invasive prostatic urethral lift: surgical technique and multinational experience.

Authors:  Thomas A McNicholas; Henry H Woo; Peter T Chin; Damien Bolton; Manuel Fernández Arjona; Karl-Dietrich Sievert; Martin Schoenthaler; Ulrich Wetterauer; Eric J E J Vrijhof; Steven Gange; Francesco Montorsi
Journal:  Eur Urol       Date:  2013-01-19       Impact factor: 20.096

View more
  1 in total

1.  Urinary and sexual function changes in benign prostatic hyperplasia patients before and after transurethral columnar balloon dilatation of the prostate.

Authors:  Dong-Peng Zhang; Zheng-Bo Pan; Hai-Tao Zhang
Journal:  World J Clin Cases       Date:  2022-07-16       Impact factor: 1.534

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.